Axinn partner Stacie Ropka participated in a panel discussion at the World Biosimilar Congress Europe conference in Basel, Switzerland. "Legal and IP Strategies to Strengthen Biosimilar Medicine Developers" addressed the following topics:

• How Brexit will impact the IP landscape and business strategies for the sector
• Opportunities for biosimilar medicine developers
• Establishing sustainability for second medical use patents
• How to take advantage of the IP and regulatory environments to grow the generic and value added medicines business
• Antitrust case law and latest developments
• Inconsistencies in the SPC case law